Milan, Italy, and Morristown, NJ, USA, January 6, 2026, 07:00 am CET - Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Morristown, NJ, USA, and Milan, Italy, December 8, 2025, 07:00 am CET- Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Milan, Italy, September 16, 2025, 07:00 am CEST - Newron presents H1 2025 results and provides business update
Milan, Italy, and Morristown, NJ, USA, August 12, 2025, 07:00 am CET - Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Milan, Italy and Morristown, NJ, USA – August 11 , 2025, 7:00 am CET – Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Milan, Italy and Morristown, NJ, USA 24 May 12, 2025, 7 am CET Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Milan, Italy, April 23, 2025, 11:30 am CET Newron Pharmaceuticals Annual General Meeting 2025: Chris Martin elected as new Chairman of the Board of Directors
Milan, Italy, April 1, 2025, 07:00 am CET Newron presents 2024 financial results and provides 2025 outlook
Milan, Italy and Morristown, NJ, USA 24 March, 2025, 5:45 pm CET Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
Milan, Italy, December 13, 2024, 7 am CET Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
Milan, Italy, September 19, 2024, 7 am CET Newron presents H1 2024 results and provides business update
Milan, Italy, May 13, 2024, 07:00 am CET Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Milan, Italy, April 30, 2024, 07:00 am CET Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Milan, Italy, April 17, 2024, 11:30 am CET Newron announces AGM 2024 results
Milan, Italy, March 19, 2024, 07:00 am CET Newron presents 2023 financial results and provides 2024 outlook
Milan, Italy, March 15, 2024, 07:00 am CET Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Milan, Italy, March 14, 2024, 17:45 CET Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares